Ohio's adult obesity rate of 35.3% affects over 3.3 million residents. Franklin County (Columbus) is the most populous county and has seen obesity rates climb sharply. Southeast Ohio's Appalachian counties report obesity rates above 42%. Across metro areas like Columbus, Cleveland, Cincinnati, Toledo, obesity-related conditions including type 2 diabetes, hypertension, and cardiovascular disease affect hundreds of thousands of Ohio residents every year.
GLP-1 receptor agonists — semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®) — are FDA-approved prescription medications that produce average weight loss of 15–22% of body weight in clinical trials, with proven reductions in cardiovascular event risk. Thanks to Ohio's telehealth law (Ohio Revised Code § 4731.296), these medications are now accessible from any city or rural county in the state through a licensed online physician.[1][2]
Medically reviewed by
Dr. Sarah Mitchell, MD, ABOM
Board-Certified in Obesity Medicine • Last reviewed: June 5, 2026
Complete a secure health questionnaire from anywhere in Ohio — Columbus, Cleveland, Cincinnati, Toledo, or any rural county. Takes under 10 minutes.
A board-certified MD licensed in Ohio reviews your health profile and conducts a HIPAA-compliant telehealth consultation — within 24–48 hours.
If approved, your GLP-1 medication ships from a licensed US pharmacy directly to your Ohio address — no pharmacy trip, no waiting room.
Licensed telehealth GLP-1 providers serve every corner of Ohio. Select your city below for local information and to start your consultation.
Whether you live in urban Franklin County, or a rural county, our Ohio-licensed telehealth providers can prescribe GLP-1 medications online. Choose your county:
Connect with experienced, US-licensed physicians specializing in metabolic health and GLP-1 therapy. All providers are board-certified and committed to evidence-based care.
Yes. Ohio telehealth law (Ohio Revised Code § 4731.296) explicitly permits licensed physicians to prescribe medications — including GLP-1 receptor agonists — via telemedicine after a valid patient-physician relationship is established through an online consultation. You do not need to visit a clinic in person.
Ohio has an adult obesity rate of 35.3%, ranking above national average in the United States. Cities such as Columbus, Cleveland, Cincinnati see high rates of obesity-related conditions including type 2 diabetes and cardiovascular disease. GLP-1 medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are clinically proven to reduce body weight by 15–22% and improve metabolic health markers.
Ohio-licensed telehealth providers can prescribe all FDA-approved GLP-1 medications, including semaglutide (Ozempic for diabetes, Wegovy for weight loss), tirzepatide (Mounjaro for diabetes, Zepbound for weight loss), and liraglutide (Saxenda for weight loss, Victoza for diabetes). Eligibility is assessed individually during your consultation.
Most Ohio patients complete their free health assessment online and receive a physician consultation within 24–48 hours. If approved, your prescription is sent to a licensed US pharmacy and medications typically arrive within 3–5 business days by home delivery — no in-person pharmacy visit required.
Ohio Medicaid may cover GLP-1 medications when prescribed for FDA-approved type 2 diabetes indications. Coverage for weight loss indications (Wegovy, Zepbound) varies by commercial insurance plan. Manufacturer patient assistance and savings programs can significantly reduce out-of-pocket costs for eligible Ohio residents who do not have coverage.
Black Box Warning: In rodent studies, semaglutide and tirzepatide caused thyroid C-cell tumors. It is unknown whether GLP-1 receptor agonists cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. These medications are contraindicated in patients with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Common side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, headache, and injection site reactions. These typically diminish as dosage is gradually escalated.
Serious side effects may include pancreatitis, gallbladder problems, kidney injury, hypoglycemia (with insulin), and allergic reactions. Consult your healthcare provider immediately if you experience severe symptoms.
Contraindications: History of medullary thyroid carcinoma, MEN 2, pancreatitis, pregnancy or breastfeeding, severe gastrointestinal disease. This is not a complete list — always discuss your full medical history with your physician.
Clinical References:
